Impact of Infectious and Inflammatory Disease on Cytochrome P450–Mediated Drug Metabolism and Pharmacokinetics
2009; Wiley; Volume: 85; Issue: 4 Linguagem: Inglês
10.1038/clpt.2008.302
ISSN1532-6535
Autores Tópico(s)Drug-Induced Hepatotoxicity and Protection
ResumoClinical Pharmacology & TherapeuticsVolume 85, Issue 4 p. 434-438 Development Impact of Infectious and Inflammatory Disease on Cytochrome P450–Mediated Drug Metabolism and Pharmacokinetics ET Morgan, Corresponding Author ET Morgan [email protected] Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia, USASearch for more papers by this author ET Morgan, Corresponding Author ET Morgan [email protected] Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia, USASearch for more papers by this author First published: 11 February 2009 https://doi.org/10.1038/clpt.2008.302Citations: 78Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Abstract Infection and inflammation are associated with downregulation of hepatic and extrahepatic cytochrome P450s as well as other drug-metabolizing enzymes and transporters. We review the genesis of inflammatory reactions and discuss the relevance of the inflammation-related regulation of cytochrome P450 enzymes to clinical drug–disease and drug–drug interactions. An understanding of the enzyme specificity and mechanisms of regulation will allow us to make better decisions about adjusting drug dosage regimens when a patient's inflammatory status changes. Clinical Pharmacology & Therapeutics (2009); 85, 4, 434–438 doi:10.1038/clpt.2008.302 References 1Petrovic, V., Teng, S. & Piquette-Miller, M. Regulation of drug transporters during infection and inflammation. Mol. Interv. 7, 99– 111 (2007). 2Medzhitov, R. Origin and physiological roles of inflammation. Nature 454, 428– 435 (2008). 3Fulop, A.K. Genetics and genomics of hepatic acute phase reactants: a mini-review. Inflamm. Allergy Drug Targets 6, 109– 115 (2007). 4Renton, K.W. Cytochrome P450 regulation and drug biotransformation during inflammation and infection. Curr. Drug Metab. 5, 235– 243 (2004). 5Aitken, A.E., Richardson, T.A. & Morgan, E.T. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu. Rev. Pharmacol. Toxicol. 46, 123– 149 (2006). 6Xu, D.X., Wang, J.P., Sun, M.F., Chen, Y.H. & Wei, W. Lipopolysaccharide downregulates the expressions of intestinal pregnane x receptor and cytochrome p450 3a11. Eur. J. Pharmacol. 536, 162– 170 (2006). 7Kraemer, M.J., Furukawa, C.T., Koup, J.R., Shapiro, G.G., Pierson, W.E. & Bierman, C.W. Altered theophylline clearance during an influenza B outbreak. Pediatrics 69, 476– 480 (1982). 8Kacevska, M., Robertson, G.R., Clarke, S.J. & Liddle, C. Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing. Expert Opin. Drug Metab. Toxicol. 4, 137– 149 (2008). 9Morgan, E.T. et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab. Dispos. 36, 205– 216 (2008). 10Shord, S.S. et al. Cytochrome P450 2C9 mediated metabolism in people with and without cancer. Int. J. Clin. Pharmacol. Ther. 46, 365– 374 (2008). 11Mahmood, I. & Green, M.D. Drug interaction studies of therapeutic proteins or monoclonal antibodies. J. Clin. Pharmacol. 47, 1540– 1554 (2007). 12Elkahwaji, J. et al. Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy. Biochem. Pharmacol. 57, 951– 954 (1999). 13Aitken, A.E. & Morgan, E.T. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab. Dispos. 35, 1687– 1693 (2007). 14Sunman, J.A., Hawke, R.L., LeCluyse, E.L. & Kashuba, A.D. Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. Drug Metab. Dispos. 32, 359– 363 (2004). 15Ashino, T., Arima, Y., Shioda, S., Iwakura, Y., Numazawa, S. & Yoshida, T. Effect of interleukin-6 neutralization on cyp3a11 and metallothionein-1/2 expressions in arthritic mouse liver. Eur. J. Pharmacol. 558, 199– 207 (2007). 16Chaluvadi, M.R., Nyagode, B.A., Kinloch, R.D. & Morgan, E.T. TLR4-dependent and -independent regulation of hepatic cytochrome P450 in mice with chemically induced inflammatory bowel disease. Biochem. Pharmacol. 77, 464– 471 (2009). 17Chaluvadi, M.R. et al. Regulation of hepatic cytochrome P450 expression in mice with intestinal or systemic infections of Citrobacter rodentium. Drug Metab. Dispos. 37, 366– 374 (2009). 18Fakhoury, M., Lecordier, J., Medard, Y., Peuchmaur, M. & Jacqz-Agrain, E. Impact of inflammation on the duodenal mRNA expression of CYP3A and p-glycoprotein in children with Crohn's disease. Inflamm. Bowel Dis. 12, 745– 749 (2006). 19Hayden, M.S., West, A.P. & Ghosh, S. NF-kappaB and the immune response. Oncogene 25, 6758– 6780 (2006). 20Zhou, C. et al. Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation. J. Clin. Invest. 116, 2280– 2289 (2006). 21Gu, X. et al. Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents. J. Biol. Chem. 281, 17882– 17889 (2006). 22Tian, Y., Ke, S., Denison, M.S., Rabson, A.B. & Gallo, M.A. Ah receptor and NF-kappaB interactions, a potential mechanism for dioxin toxicity. J. Biol. Chem. 274, 510– 515 (1999). 23Assenat, E., Gerbal-chaloin, S., Maurel, P., Vilarem, M.J. & Pascussi, J.M. Is nuclear factor kappa-B the missing link between inflammation, cancer and alteration in hepatic drug metabolism in patients with cancer? Eur. J. Cancer 42, 785– 792 (2006). 24Richardson, T.A. & Morgan, E.T. Hepatic cytochrome P450 gene regulation during endotoxin-induced inflammation in nuclear receptor knockout mice. J. Pharmacol. Exp. Ther. 314, 703– 709 (2005). 25Iber, H., Chen, Q., Cheng, P.Y. & Morgan, E.T. Suppression of CYP2C11 gene transcription by interleukin-1 mediated by NF-kappaB binding at the transcription start site. Arch. Biochem. Biophys. 377, 187– 194 (2000). 26Tindberg, N., Bengtsson, I. & Hu, Y. A novel lipopolysaccharide-modulated jun binding repressor in intron 2 of CYP2E1. J. Neurochem. 89, 1336– 1346 (2004). 27Jover, R., Bort, R., Gómez-Lechón, M.J. & Castell, J.V. Down-regulation of human CYP3A4 by the inflammatory signal interleukin 6: molecular mechanism and transcription factors involved. FASEB J. 16, 1799– 1801 (2002). 28Xu, D.X. et al. Kupffer cells and reactive oxygen species partially mediate lipopolysaccharide-induced downregulation of nuclear receptor pregnane x receptor and its target gene cyp3a in mouse liver. Free Radic. Biol. Med. 37, 10– 22 (2004). 29Kim, J.Y. & Lee, S.M. Vitamins C and E protect hepatic cytochrome P450 dysfunction induced by polymicrobial sepsis. Eur. J. Pharmacol. 534, 202– 209 (2006). 30Lee, C.M., Kim, B.Y., Li, L. & Morgan, E.T. Nitric oxide-dependent proteasomal degradation of cytochrome P450 2B proteins. J. Biol. Chem. 283, 889– 898 (2008). 31Aitken, A.E., Lee, C.M. & Morgan, E.T. Roles of nitric oxide in inflammatory downregulation of human cytochromes P450. Free Radic. Biol. Med. 44, 1161– 1168 (2008). 32Siewert, E., Bort, R., Kluge, R., Heinrich, P.C., Castell, J. & Jover, R. Hepatic cytochrome P450 down-regulation during aseptic inflammation in the mouse is interleukin 6 dependent. Hepatology 32, 49– 55 (2000). 33Richardson, T.A. et al. Hepatic and renal cytochrome P450 gene regulation during Citrobacter rodentium infection in wild-type and toll-like receptor 4 mutant mice. Drug Metab. Dispos. 34, 354– 360 (2006). Citing Literature Volume85, Issue4Genes vs. EnvironmentApril 2009Pages 434-438 ReferencesRelatedInformation
Referência(s)